Profiles

Keywords
Last Name
Institution

Connection

John Somberg to United States

This is a "connection" page, showing publications John Somberg has written about United States.

 
Connection Strength
 
 
 
4.388
 
  1. Somberg J. OUS results, clinical studies and therapeutic innovation in America. Am J Ther. 2014 Jul-Aug; 21(4):233.
    View in: PubMed
    Score: 0.103
  2. Somberg J. Courts, patents, litigation & patient care. Am J Ther. 2014 May-Jun; 21(3):142.
    View in: PubMed
    Score: 0.102
  3. Somberg JC, McEwen P, Molnar J. Assessment of cardiovascular and noncardiovascular medical device recalls. Am J Cardiol. 2014 Jun 01; 113(11):1899-903.
    View in: PubMed
    Score: 0.101
  4. Somberg J. The conflict of interest charade. Am J Ther. 2013 Nov-Dec; 20(6):591.
    View in: PubMed
    Score: 0.098
  5. Somberg J. The Supremes got it right. Am J Ther. 2013 Jul-Aug; 20(4):315.
    View in: PubMed
    Score: 0.096
  6. Somberg JC. A perspective on the support of scientific research. Am J Ther. 2013 May-Jun; 20(3):231.
    View in: PubMed
    Score: 0.095
  7. Somberg JC. Conflating the approval process and clinical research with pharmacoeconomic evaluation. Am J Ther. 2013 Jan; 20(1):1.
    View in: PubMed
    Score: 0.093
  8. Somberg JC. Proposed accelerated FDA approvals for special medical use. Am J Ther. 2012 Nov; 19(6):393-4.
    View in: PubMed
    Score: 0.092
  9. Somberg JC. Making America more competitive: a paradigm shift in drug and device development. Am J Ther. 2012 Sep; 19(5):315-6.
    View in: PubMed
    Score: 0.091
  10. Somberg JC. Drug shortages and ensuring the U.S. supply of needed pharmaceuticals. Am J Ther. 2012 Mar; 19(2):65.
    View in: PubMed
    Score: 0.088
  11. Somberg JC. The device development pinata. Am J Ther. 2011 Sep; 18(5):339.
    View in: PubMed
    Score: 0.085
  12. Somberg JC. Are we facilitating therapeutic innovation? Am J Ther. 2011 Jul; 18(4):279.
    View in: PubMed
    Score: 0.084
  13. Somberg JC. Has the food and drug administration changed the drug approval process? Am J Ther. 2011 May; 18(3):179.
    View in: PubMed
    Score: 0.083
  14. Somberg JC. Inappropriate attack on device development. Am J Ther. 2011 Mar-Apr; 18(2):91.
    View in: PubMed
    Score: 0.082
  15. Somberg JC. Unfinished business in health care reform. Am J Ther. 2011 Jan; 18(1):1.
    View in: PubMed
    Score: 0.081
  16. Somberg JC. The Food and Drug Administration's paternalism. Am J Ther. 2010 Nov-Dec; 17(6):533-4.
    View in: PubMed
    Score: 0.080
  17. Somberg JC, Preston RA, Ranade V, Molnar J. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.078
  18. Somberg J. Device safety and effectiveness. Am J Ther. 2010 Jul-Aug; 17(4):357.
    View in: PubMed
    Score: 0.078
  19. Somberg JC. Is the device development process adequate. Am J Ther. 2010 Mar-Apr; 17(2):123-4.
    View in: PubMed
    Score: 0.076
  20. Somberg JC. Medical isotope shortages. Am J Ther. 2009 Sep-Oct; 16(5):378.
    View in: PubMed
    Score: 0.074
  21. Somberg J. Health care reform. Am J Ther. 2009 Jul-Aug; 16(4):281-2.
    View in: PubMed
    Score: 0.073
  22. Somberg JC. The extrapolation of study results in the device approval process. Am J Cardiol. 2009 May 01; 103(9):1323-4.
    View in: PubMed
    Score: 0.071
  23. Somberg JC. The stimulus package and medical therapeutics. Am J Ther. 2009 Mar-Apr; 16(2):105.
    View in: PubMed
    Score: 0.071
  24. Somberg JC, Molnar J. The management of acute heart failure and diuretic therapy. Am J Ther. 2009 Jan-Feb; 16(1):93-7.
    View in: PubMed
    Score: 0.070
  25. Somberg JC. Securing the US pharmaceutical supply. Am J Ther. 2008 May-Jun; 15(3):197.
    View in: PubMed
    Score: 0.067
  26. Nada A, Baxter S, Loraas E, Somberg JC. Incidence and predictors of screen failures due to positive urine tests for alcohol, drugs of abuse, and cotinine among normal healthy research volunteers (NHRVs): analysis of data from 687 NHRVs screened at a large clinical pharmacology unit in the United States. Am J Ther. 2008 May-Jun; 15(3):214-20.
    View in: PubMed
    Score: 0.067
  27. Somberg J. FDA user fees and innovation. Am J Ther. 2008 Mar-Apr; 15(2):97.
    View in: PubMed
    Score: 0.066
  28. Somberg J. Mandatory post marketing studies. Am J Ther. 2007 Jul-Aug; 14(4):321.
    View in: PubMed
    Score: 0.063
  29. Somberg J. Patent foramen ovale closure devices: thoughts from the circulatory device advisory panel. Am J Cardiol. 2007 Sep 01; 100(5):905-6.
    View in: PubMed
    Score: 0.063
  30. Somberg J. Biologic generics. Am J Ther. 2007 May-Jun; 14(3):230.
    View in: PubMed
    Score: 0.063
  31. Somberg J. The drug safety review process. Am J Ther. 2007 Mar-Apr; 14(2):119.
    View in: PubMed
    Score: 0.062
  32. Somberg J. The report of the Institute of Medicine on drug safety. Am J Ther. 2007 Jan-Feb; 14(1):1-2.
    View in: PubMed
    Score: 0.061
  33. Somberg J. Off-label promotion. Am J Ther. 2006 Sep-Oct; 13(5):387.
    View in: PubMed
    Score: 0.060
  34. Somberg J. Surrogate endpoints and drug approval. Am J Ther. 2006 Sep-Oct; 13(5):388.
    View in: PubMed
    Score: 0.060
  35. Somberg JC. Pharmaceutical companies and medical therapeutics education. Am J Ther. 2006 Mar-Apr; 13(2):93.
    View in: PubMed
    Score: 0.058
  36. Somberg JC. An opportunity to distance the FDA from Washington politics. Am J Ther. 2005 Nov-Dec; 12(6):475.
    View in: PubMed
    Score: 0.057
  37. Somberg JC. Nesiritide: the wrong controversy. Am J Ther. 2005 Sep-Oct; 12(5):377-8.
    View in: PubMed
    Score: 0.056
  38. Somberg J. Intellectual property. Am J Ther. 2005 Jul-Aug; 12(4):285.
    View in: PubMed
    Score: 0.055
  39. Somberg JC. The new drug evaluation process: risk benefit ratio. Am J Ther. 2005 May-Jun; 12(3):199-200.
    View in: PubMed
    Score: 0.055
  40. Somberg J. Lessons learned from the COX-2 advisory hearings. Am J Ther. 2005 Mar-Apr; 12(2):105.
    View in: PubMed
    Score: 0.054
  41. Somberg J. The provisional approval step. Am J Ther. 2005 Jan-Feb; 12(1):1-2.
    View in: PubMed
    Score: 0.053
  42. Somberg J. The politics of therapeutics. Am J Ther. 2004 Nov-Dec; 11(6):422.
    View in: PubMed
    Score: 0.053
  43. Somberg J. Drug trial registries. Am J Ther. 2004 Sep-Oct; 11(5):327.
    View in: PubMed
    Score: 0.052
  44. Somberg J. What is a journal. Am J Ther. 2004 Jul-Aug; 11(4):243.
    View in: PubMed
    Score: 0.052
  45. Somberg J. Obesity therapeutics in the shadows: editorial. Am J Ther. 2004 May-Jun; 11(3):155.
    View in: PubMed
    Score: 0.051
  46. Somberg J. Should statins go OTC. Am J Ther. 2004 Jan-Feb; 11(1):1-2.
    View in: PubMed
    Score: 0.050
  47. Somberg J. Therapeutics, drug pricing and innovation. Am J Ther. 2003 Nov-Dec; 10(6):381.
    View in: PubMed
    Score: 0.049
  48. Somberg J. Clinical trials registries. Am J Ther. 2003 Sep-Oct; 10(5):309-10.
    View in: PubMed
    Score: 0.049
  49. Somberg JC. SARS challenges therapeutics. Am J Ther. 2003 May-Jun; 10(3):161.
    View in: PubMed
    Score: 0.048
  50. Somberg JC. Hypertension therapeutics in turmoil. Am J Ther. 2003 Mar-Apr; 10(2):81-2.
    View in: PubMed
    Score: 0.047
  51. Somberg JC. Free exchange of ideas. Am J Ther. 2003 Jan-Feb; 10(1):1.
    View in: PubMed
    Score: 0.046
  52. Gallik DM, Singer I, Meissner MD, Molnar J, Somberg JC. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2002 Nov 01; 90(9):964-8.
    View in: PubMed
    Score: 0.046
  53. Somberg JC. Biologic problems. Am J Ther. 2002 Nov-Dec; 9(6):471.
    View in: PubMed
    Score: 0.046
  54. Somberg JC. Restricting physician prescribing. Am J Ther. 2002 Sep-Oct; 9(5):369.
    View in: PubMed
    Score: 0.045
  55. Somberg JC. Old drugs, new bottles, therapeutic advantage? Am J Ther. 2002 Jul-Aug; 9(4):273-4.
    View in: PubMed
    Score: 0.045
  56. Somberg JC. Clinical research oversight. Am J Ther. 2002 Mar-Apr; 9(2):85.
    View in: PubMed
    Score: 0.044
  57. Somberg JC. The generic conundrum. Am J Ther. 2002 Mar-Apr; 9(2):87-8.
    View in: PubMed
    Score: 0.044
  58. Somberg JC. Bioterrorism 2002. Am J Ther. 2002 Jan-Feb; 9(1):3.
    View in: PubMed
    Score: 0.043
  59. Somberg JC. A challenge to America. Am J Ther. 2001 Nov-Dec; 8(6):383.
    View in: PubMed
    Score: 0.043
  60. Somberg JC. A new therapeutic millennium [correction of millenium]. Am J Ther. 2001 Nov-Dec; 8(6):385-6.
    View in: PubMed
    Score: 0.043
  61. Somberg JC. Stem-cell research. Am J Ther. 2001 Sep-Oct; 8(5):307.
    View in: PubMed
    Score: 0.042
  62. Somberg JC. Do we need to accredit clinical research? Am J Ther. 2001 Jul-Aug; 8(4):223-4.
    View in: PubMed
    Score: 0.042
  63. Somberg JC. Proposed product labeling changes: does it really matter? Am J Ther. 2001 May-Jun; 8(3):145-6.
    View in: PubMed
    Score: 0.041
  64. Somberg JC. Are we overregulated? Am J Ther. 2001 Jan-Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.040
  65. Somberg JC. A choice, not an echo. Am J Ther. 2000 Sep; 7(5):281.
    View in: PubMed
    Score: 0.040
  66. Somberg JC. Is clinical research oversight adequate in the United States? Am J Ther. 2000 Sep; 7(5):283-4.
    View in: PubMed
    Score: 0.040
  67. Somberg JC. Adverse drug reaction reporting. Am J Ther. 2000 Aug; 7(4):227-8.
    View in: PubMed
    Score: 0.039
  68. Somberg JC. Medical judgment and therapeutics. Am J Ther. 1999 Nov; 6(6):291-2.
    View in: PubMed
    Score: 0.037
  69. Somberg JC, Borer JS. Advances in cardiovascular pharmacology: protocol design and methodology--the US regulatory process. Am J Ther. 1999 May; 6(3):175-8.
    View in: PubMed
    Score: 0.036
  70. Somberg JC. Reactions to prescribed drugs kill thousands annually. Am J Ther. 1998 May; 5(3):133.
    View in: PubMed
    Score: 0.034
  71. Somberg JC. Sharing regulatory review costs. J Clin Pharmacol. 1992 Oct; 32(10):867.
    View in: PubMed
    Score: 0.023
  72. Somberg JC, Miura D, Keefe DL. The treatment of ventricular rhythm disturbances. Am Heart J. 1986 Jun; 111(6):1162-76.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.